EMA Withdrawn: Nespo (darbepoetin alfa) — Dompé Biotec S.p.A.

View source ↗

Summary

EMA has withdrawn Nespo (darbepoetin alfa) from Dompé Biotec S.p.A.'s portfolio.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Cancer
• Kidney Failure Chronic

Drugs mentioned

• Nespo (darbepoetin alfa)

Snippet

Status: Withdrawn. Therapeutic area: Kidney Failure, Chronic;Anemia;Cancer. MAH: Dompé Biotec S.p.A.. Decision date: 28/10/2008